# Terlipressin Alone Versus the Standard Therapy With Catecholamines for Hepatic Patients With Septic Shock- Prospective Single Center Randomized Controlled Study.

> **NCT03608514** · PHASE2,PHASE3 · UNKNOWN · sponsor: **National Hepatology & Tropical Medicine Research Institute** · enrollment: 100 (estimated)

## Conditions studied

- Resolution of Septic Shock With Terlipressin

## Interventions

- **DRUG:** Experimental

## Key facts

- **NCT ID:** NCT03608514
- **Lead sponsor:** National Hepatology & Tropical Medicine Research Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-01
- **Primary completion:** 2020-07
- **Final completion:** 2020-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2018-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03608514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03608514, "Terlipressin Alone Versus the Standard Therapy With Catecholamines for Hepatic Patients With Septic Shock- Prospective Single Center Randomized Controlled Study.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03608514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*